Molecular crosstalk between inflammation and metabolic disorders

Emerging evidence suggests that chronic low-grade inflammation plays a critical role in the pathogenesis of metabolic disorders such as obesity, type 2 diabetes mellitus (T2DM), non-alcoholic fatty liver disease (NAFLD), and metabolic syndrome. This phenomenon termed immunometabolic crosstalk is driven by complex interactions between immune signaling pathways, metabolic tissues, and environmental factors. This study systematically reviewed the molecular mechanisms underpinning the bidirectional relationship between inflammation and metabolic dysfunction, with the aim of identifying key pathways, biomarkers, and potential therapeutic targets. A systematic review of 40 peer-reviewed articles published between 2020 and 2023 was conducted. The analysis focused on inflammatory signaling cascades (e.g., TLRs, NLRP3 inflammasomes), immune cell infiltration, mitochondrial and endoplasmic reticulum stress, gut microbiota dynamics, and epigenetic modifications. Visual tools including bar charts, pie charts, and line graphs were used to present patterns in molecular mechanisms and intervention outcomes. The findings revealed that Toll-like receptor 4 (TLR4)-MyD88-NF-κB signaling and NLRP3 inflammasome activation are central drivers of chronic inflammation in metabolic disorders. These pathways promote the secretion of pro-inflammatory cytokines such as TNF-α, IL-6, IL-1β, and MCP-1, which impair insulin signaling and glucose metabolism. Adipose tissue was identified as a key immunometabolic organ, while mitochondrial dysfunction and gut-derived endotoxemia contributed to systemic inflammation. Epigenetic regulators, including miRNAs and histone modifications, influenced the expression of immune-metabolic genes. Pharmacological agents (e.g., IL-1 blockers, NLRP3 inhibitors), lifestyle interventions (e.g., diet, exercise), and microbiota-based therapies (e.g., probiotics, fecal transplants) significantly reduced inflammatory markers and improved metabolic outcomes. Metabolic disorders are underpinned by complex immunological mechanisms that extend beyond traditional endocrinology. Targeting immunometabolic crosstalk through multi-modal interventions offers a promising strategy for the prevention and management of obesity-related diseases. Future research should prioritize longitudinal studies, multi-omics integration, and personalized approaches that address the dual burden of inflammation and metabolic dysfunction.